CISPLATINO Pfizer 50 mg/50 ml soluzione per infusione

DRUG2 trials

Sponsors

IRCCS Istituto Nazionale Tumori Fondazione Pascale, Humanitas Mirasole S.p.A.

Conditions

Recurrent Metastatic Nasopharingeal Carcinomalocally advanced cholangiocarcinoma

Phase 2

Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanced cholangIOcarciNoma: an exploratory and translational study.

RecruitingCTIS2024-518656-23-00

IRCCS Istituto Nazionale Tumori Fondazione Pascalelocally advanced cholangiocarcinoma

Start: 2023-09-01Target: 38Updated: 2025-12-05

Phase 3

Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population

Not yet recruitingCTIS2025-522472-85-00

Humanitas Mirasole S.p.A.Recurrent Metastatic Nasopharingeal Carcinoma

Target: 49Updated: 2026-01-08